AZIENDA PROVINCIALE PER I SERVIZI SANITARI

Their core work

Azienda Provinciale per i Servizi Sanitari (APSS) is the provincial public health authority of Trentino, Italy, responsible for delivering hospital care, primary care, and specialized medical services across the province. In H2020 projects, they contribute real-world clinical environments and patient populations for testing digital health tools, elderly care technologies, and advanced cancer treatment protocols. Their most recent work focuses on clinical trials comparing proton therapy versus photon therapy for esophageal cancer, reflecting their role as a healthcare provider with active involvement in translational oncology research.

What they specialise in

How they've shifted over time

In their early H2020 participation (2015-2017), APSS focused on digital health and ICT-enabled care for elderly populations, contributing clinical sites for testing interoperable care platforms and assistive technologies. From 2021 onward, their focus shifted decisively toward oncology, specifically proton therapy for esophageal cancer via the PROTECT-trial. This evolution suggests a move from technology validation roles toward direct involvement in advanced clinical research.

APSS is moving from passive ICT testing toward active participation in advanced oncology research, making them a relevant partner for cancer treatment and radiation therapy projects.

How they like to work

APSS never coordinates projects — they participate as a partner or third party, which is typical for public health authorities contributing clinical infrastructure rather than driving research agendas. With 60 unique partners across 17 countries from just 4 projects, they work in large, multinational consortia. This means they are experienced in multi-site collaboration and comfortable operating within complex partnership structures, but you should not expect them to lead project management or dissemination.

Despite only 4 projects, APSS has worked with 60 distinct partners across 17 countries, indicating they join large-scale European consortia. Their network spans a broad geographic range rather than clustering around specific regional partners.

What sets them apart

As a provincial health authority (not a university hospital or research institute), APSS offers something consortia often struggle to find: direct access to real patient populations and routine clinical workflows in a public healthcare system. Their location in Trentino, a region known for strong health governance and digital health infrastructure, adds credibility. For projects needing clinical validation sites in Italy, they provide institutional backing and ethical approval pathways that academic partners alone may not offer.

Highlights from their portfolio

• PROTECT-trial
  Their most recent and longest-running project (2021-2027), a landmark multinational clinical trial comparing proton vs photon therapy for esophageal cancer — a topic with direct translational impact.
• UNCAP
  Their largest funded project (EUR 155,938), focused on building interoperable elderly care platforms — represents their strongest commitment to a single H2020 initiative.
• ANTI-SUPERBUGS PCP
  A pre-commercial procurement project tackling antimicrobial resistance, notable for its innovative funding mechanism (PCP) and critical public health relevance.